Association of SIRT1 single gene nucleotide polymorphisms and serum SIRT1 levels with laryngeal squamous cell carcinoma patient survival rate

1.Introduction

Laryngeal squamous cell carcinoma (LSCC) is one of the most common malignancies of the upper aerodigestive tract, with high mortality and poor prognosis for patients. In 2020, 184615 new cases of LSCC were diagnosed, and 99840 patients died from this cancer worldwide [1]. World Health Organization has estimated that the incidence and mortality of LSCC will have increased from 52.4% to 64.5%, respectively, by 2040 [2]. The most significant increment is projected in countries with a low Human Development Index [2]. This cancer occurs much more frequently in men than in women. According to The Global Cancer Observatory, the age-standardized incidence rate of laryngeal cancer is 3.6/100,000 people among males and 0.49/1,00,000 people among females per year [1]. This can be explained by the fact that men are more likely to have harmful habits. Laryngeal cancer is a multifactorial disease; however, it is generally accepted that tobacco and high-intensity alcohol consumption are the main risk factors for LSCC [3, 4, 6, 7]. Epidemiological studies have consistently linked pro-inflammatory dietary intake, human papillomavirus infection, environmental and occupational exposures with increased risk of LSCC [8, 9, 10, 11, 12, 13, 14]. A rising focus on identifying genetic and epigenetic factors to develop new diagnostic tools and treatment for laryngeal cancer can be seen [15]. Several studies have shown an essential role of gene variants, especially in combination with toxins, such as alcohol and cigarette smoke, in the etiopathology and the overall risk/survival rate of LSCC [15].

Despite the rather evident symptoms (hoarseness, dysphonia, dyspnea, and swallowing dysfunction) that may onset quite early in patients with laryngeal malignancies, in many cases, cancer already is at the advanced stage (III or IV) of the disease when diagnosed. Unfortunately, modern treatment strategies do not achieve improvement in therapeutic outcomes and survival [16, 17]. Therefore, to implement effective strategies for the prevention and early diagnosis, LSCC needs to be determined from epidemiological and clinical data and modern diagnostic methods based on genetic discoveries.

A silent information regulator two homolog 1 (SIRT1) is a nicotinamide adenine dinucleotide (NAD+)-dependent enzyme which plays a critical role in a wide variety of cellular processes, such as genomic stability, glucose, and lipid metabolism, gene transcription, oxidative stress, and aging process via autophagy [18, 19, 20, 21, 22, 23, 24, 25, 26]. Dysregulation of SIRT1 is involved in the pathogenesis of diabetes, neurodegenerations, depression, anorexia nervosa, and cardiovascular diseases and has been proposed as a therapeutic target [18, 19, 21, 25, 27]. Moreover, SIRT1 is a multifunctional protein, possibly essential in tumorigenesis pathways, which can act both as a tumor promoter and tumor suppressor depending on the oncogenes specific to particular tumors [28]. Meta-analyses carried out by Wang et al. in 2017 and Sun et al. in 2019 revealed that overexpression of SIRT1 indicates a poor prognosis for patients with various cancers [29, 30]. Ye et al. in their study, have demonstrated the inhibition of proliferation, invasion, and migration of lung cancer through downregulation of SIRT1 expression and activation of cell autophagy [31]. Several studies have established an association between SIRT1 expression and a reasonable prognosis of head and neck tumors [32, 33]. The pathogenesis of laryngeal cancer is multifactorial, and the association of SIRT1 expression with the clinical characteristics and prognosis of LSCC has not been fully identified.

Genetic variants may cause different SIRT1 expressions, and it could play an essential role in laryngeal carcinogenesis. However, just one study has investigated the involvement of SIRT1 single nucleotide polymorphism (SNP) in laryngeal cancer and has not found any associations between LSCC and SIRT1 rs12778366 gene polymorphism [34].

The study aimed to evaluate associations between SNPs of SIRT1 (rs3818292, rs3758391, and rs7895833), serum SIRT1 levels, and the 5-year survival rate of patients with LSCC.

2.Materials and methods

3.Results

The distributions of the analyzed SNPs (SIRT1 rs3818292, rs3758391, and rs7895833) in the control group matched the Hardy-Weinberg equilibrium (HWE) (p> 0.001) (Table 2).

We analyzed the distributions of frequencies of the following genotypes and alleles of SIRT1 rs3818292, rs3758391, and rs7895833 in the LSCC and control groups. There was no statistically significant difference between these two groups (Table 3). Binomial logistic regression was performed to evaluate the impact of SIRT1 rs3818292, rs3758391, and rs7895833 on LSCC development. Our results revealed that SIRT1 rs3758391T/T genotype carriers had statistically significantly increased LSCC development odds under the codominant model (OR = 1.960 95% CI = 1.028–3.737; p= 0.041) (Table 4).

We analyzed the distributions of SIRT1 rs3818292, rs3758391, and rs7895833 genotype and allele frequencies between the control and patient with LSCC (in early- and advanced-stages) groups. The patient group was divided into subgroups: early (I–II stage) and advanced (III–IV stage) LSCC. The SIRT1 rs3758391 TT genotype and SIRT1 rs7895833 allele G were statistically significantly more frequent in the advanced LSCC stage subgroup than in the control group (9.5% vs. 4.4%, p= 0.029 and 18.7% vs. 12.8%, p= 0.048, respectively) (Table 5). Binomial logistic regression showed that SIRT1 rs3758391 genotype T/T carriers had statistically significantly increased odds of LSCC development into advanced stages under the codominant and recessive genetic models (OR = 2.387 95% CI = 1.091–5.222; p= 0.029 and OR = 2.287 95% CI = 1.070–4.888; p= 0.033, respectively) (Table 6).

The LSCC patients’ group was divided into four subgroups according to tumor size (T1, T2, T3, and T4). Analysis of SIRT1 rs3818292, rs3758391, and rs7895833 genotypes and allele frequencies between the control group and patients’ subgroups was performed. SIRT1 rs3758391 TT genotype was more frequent in T4 subgroup than in controls (11.9% vs. 4.4%, p= 0.012). In the overall group, rs3758391 genotype (C/C, C/T, and T/T) distributions between the T4 subgroup and controls were statistically significantly different (p= 0.039) (Table 7). Also, we found statistically significant differences in SIRT1 rs7895833 genotype (A/A, A/G, and G/G) distributions between the T4 subgroup and control groups (p= 0.030). Further analysis revealed that the SIRT1 rs7895833 G/G genotype was more frequent in the T4 subgroup than in controls (6.0% vs. 1.2%, p= 0.008) (Table 7). The binomial logistic regression revealed that SIRT1 rs3818292 genotype A/G and rs7895833 genotype A/G carriers had a statistically significantly increased odds of LSCC development into T3 under the codominant and overdominant genetic models (OR = 2.059 95% CI = 1.039–4.081, p= 0.039 and OR = 2.076 95% CI = (1.048–4.115), p= 0.036; OR = 1.796 95% CI = (1.018–3.170), p= 0.043 and OR = 1.826 95% CI = (1.035–3.223), p= 0.038, respectively) (Table 8). The SIRT1 rs3758391T/T genotype and SIRT1 rs7895833 G/G genotype increased odds of LSCC development into T4 under codominant and recessive genetic models (OR = 3.083 95% CI = 1.239–7.672, p= 0.015 and OR = 2.945 95% CI = (1.226–7.077), p= 0.016; OR = 5.183 95% CI = (1.342–20.010), p= 0.017 and OR = 5.130 95% CI = (1.342–19.618), p= 0.017 respectively) (Table 9).

We also performed a comparative analysis of the distribution of the SIRT1 rs3818292, rs3758391, and rs7895833 genotypes and alleles in the LSCC patient subgroups with metastasis to the neck lymph nodes and without metastases to the neck lymph nodes, and the control group. We found that the rs3758391 TT genotype was statistically significantly more frequent in patients without metastases to the neck lymph nodes than in healthy controls (8.3% vs. 4.4%, p= 0.037) (Table 10). However, these differences can be considered clinically irrelevant because of the low distribution incidence.

The LSCC patient group was divided into three subgroups according to the tumor differentiation grade G1, G2, and G3. Analysis of SIRT1 rs3818292, rs3758391, and rs7895833 genotypes and allele frequencies between the control group and patient subgroups was performed. The SIRT1 rs3758391 TT genotype, as well as T allele, were more frequent in the G1 subgroup than in controls (10.0% vs. 4.4%, p= 0.034; 32.2% vs. 25.1%, p= 0.048, respectively). In the overall group, rs3758391 genotype (C/C, C/T, and T/T) distributions between the G3 subgroup and controls were statistically significantly different (p= 0.003), and the further analysis showed that SIRT1 rs3758391T/T genotype was more frequent in the G3 subgroup than in controls and the G2 subgroup (20.0% vs. 4.4%, p< 0.001; 20.0% vs. 5.3%, p< 0.001, respectively) (Table 11). Moreover, we found statistically significant differences in SIRT1 rs7895833 genotype (A/A, A/G, and G/G) distributions between the G3 subgroup and the control group (p< 0.001). Further analysis revealed that the SIRT1 rs7895833 G/G genotype was more frequent in the G3 subgroup than in controls, and the G1 and G2 subgroups (12.0% vs. 1.2%, p< 0.001; 12.0% vs. 1.1%, p= 0.009 and 12.0% vs. 0.5%, p< 0.001, respectively) (Table 11). Also, the G allele at rs7895833 was statistically significantly more frequent in G3 subgroup patients than in controls (26% vs. 14.2%, p= 0.023) (Table 11). The binomial logistic regression was then applied to evaluate the impact of SIRT1 rs3818292, rs3758391, and rs7895833 on the development of LSCC with different tumor differentiation grades. No statistically significant impact was found.

SIRT1 serum levels were measured in 24 samples from the control group and 29 from the LSCC group. We did not find any statistically significant differences in SIRT1 serum levels between the LSCC and control groups (0.395 (0.714) ng/ml vs. 0.417 (0.596) ng/ml, p= 0.957) (Fig. 1). Also, we performed a comparison of the genotype distribution and serum levels of SIRT1 between the control and LSCC groups. LSCC patients with SIRT1 rs3818292 AG genotype had statistically significantly lower SIRT1 serum levels than controls (p= 0.034) (Table 12). However, the power setting of this study sample was rather low and reached 37%. Therefore, the results of SIRT1 serum level analysis were considered as the tendency.

Figure 1.

Serum SIRT1 levels in controls and patients with LSCC.

Finally, the 5-year survival rate of LSCC patients was determined. The 5-year overall survival rate of LSCC patients was 62.7% and the LSCC-specific survival rate of five years was 72.6%. Analyzing LSCC patients’ 5-year survival rate and the genotype distribution of SIRT1 (rs3818292, rs3758391, and rs7895833), we have not found a statistically significant impact of these SNPs on the patients’ 5-year survival rate (Fig. 2).

Figure 2.

Five year survival analysis of LSCC patients according to SIRT1 SNPs (rs3818292, rs3758391, and rs7895833).

4.Discussion

The SIRT1 is located on the long arm of chromosome 10 (10q21.3) [36]. Evidence from many studies has revealed that SIRT1 participates in the regulation of diverse cellular processes, including carcinogenesis [37]. In cancer development, the role of SIRT1 is dual because it can function as both a tumor promoter and a tumor suppressor [28, 37, 38, 39]. The SIRT1 acts as a tumor suppressor in holding genomic stability and negatively regulates anti-apoptotic genes, resulting in increased anticancer ability [37]. On the other hand, to meet the tumor’s high-energy needs and promote its development, SIRT1 not only induces angiogenesis but also improves HIF1α/HIF2α (regulation of the oxygen-sensitive genes controlling angiogenesis, glycolysis, and cellular apoptosis) and suppresses p53 (interference of p53-dependent apoptosis in response to DNA damage signals) [37].

Epigenetic modifications are critical for LSCC carcinogenesis [8]. Gene variants may account for different SIRT1 expressions, determining individuals’ susceptibility to specific pathologies [19, 24, 26, 40, 41, 42, 43, 44, 45]. However, little is known about the effect of polymorphism of the SIRT1 in both LSCC carcinogenesis and disease progression. Therefore, the focus of the present study was to estimate the associations between SIRT1 SNPs (rs3818292, rs3758391, rs7895833), SIRT1 serum levels, and LSCC.

In the present study, we found that SIRT1 rs3758391 T/T genotype carriers had statistically significantly increased odds of LSCC. Moreover, the current study results revealed that patients with this genotype had 2.387 odds of LSCC development into advanced stages. To the best of our knowledge, this is the first report that associates SNP in the SIRT1 gene (rs3758391) with LSCC in a pure and homogenous LSCC patients’ cohort.

According to the literature, the SRT1 rs3758391 polymorphism has been associated with healthy aging in the Chinese population and better cognitive function in older individuals [46, 47, 48]. Also, several studies have shown the role of this SIRT1 SNP in several diseases, including type 2 diabetes mellitus [49], cardiovascular diseases [50], systemic lupus erythematosus [51], and major depressive disorder [52]. Also, the accumulating evidence has suggested the importance of the SIRT1 rs3758391 in cancer development [43, 45, 53, 54]. Furthermore, Shafieian et al. found that the SIRT1 rs3758391 TT genotype increased the risk of urinary bladder cancer in the Iranian population [45]. Shaker et al. study showed that carriers of the SIRT1 rs3758391 CC genotype were more often in the colorectal cancer group than in the control group [54]. Rizk et al. study revealed that the SIRT rs3758391 polymorphism (TT genotype) was associated with the increased breast cancer risk and that the SIRT1 rs3758391T allele was a potential risk factor for breast cancer [43]. Kan et al. conducted a large-scale case-control study on diffuse large B cell lymphoma and compared results of patients with the healthy control group. They found that the SIRT1 rs3758391T allele presented an increased risk of diffuse large B cell lymphoma. Also, they noticed SIRT1 mRNA expression upregulation in diffuse large B cell lymphoma patients with TT genotype. Moreover, a worse survival rate was revealed in patients with TT genotypes. The authors concluded that the SIRT1 rs3758391 might be used as a biomarker for the prognosis of susceptibility and survival of diffuse large B cell lymphoma [53]. We did not find a significant impact of SIRT1 SNPs on LSCC patients’ 5-year survival rate in the present study. Lv et al. did not find any association between SIRT1 gene polymorphisms, including rs3758391, and lung cancer [55].

The results of the present study revealed that two SNPs of SIRT1 (rs3818292 and rs7895833) are associated with the increased odds of LSCC development into T3 and T4. No associations between the aforementioned SIRT1 SNPs and any cancer were described in the literature, so far. However, these polymorphisms of SIRT1 have been investigated mainly in the context of metabolism. They have been associated with the increased risk of visceral (rs3818292) and general (rs7895833) obesity in adults and decreased risk (a protective effect) of obesity in children (rs7895833) [56, 57, 58]. Associations of SIRT1 rs3818292 with diabetic nephropathy and nondiabetic type 1 cardiorenal syndrome have also been found [59, 60]. Kilic et al., in their study, found that SIRT1 rs7895833 might affect longevity. They observed a significant increase in serum SIRT1 level in older people and carriers of SIRT1 rs7895833, suggesting an association between SIRT1 rs7895833 SNP and longevity [61].

In the present study, we measured the serum concentration of SIRT1 in patients with LSCC and compared it with the results of the control group. We did not find any statistically significant differences between these groups. However, comparing the genotype distribution and serum levels of SIRT1 between the control and LSCC groups, we found that only LSCC patients with SIRT1 rs3818292 AG genotype demonstrated a clear tendency to significantly lower SIRT1 serum levels than controls. These findings are in some contradiction with the data of the literature. For instance, Shaker et al. in their study found that patients with colorectal cancer had a significant increment in the mean level of serum SIRT1 as compared to the control group and the mean level of serum SIRT1 was higher in patients with tumor size ⩾ 5.0 cm compared to the size < 5.0 cm [54]. Rizk et al. conducted a study on breast cancer and found significantly higher serum SIRT1 levels in breast cancer patients than in the control group. However, no significant relationship was observed between the SIRT1 levels and clinicopathological factors (types of breast cancer, tumor size, lymph node involvement, metastasis, receptor status), except the tumor differentiation grades (higher SIRT1 level in Grade 2 compared to Grade 1 patients, and in Grade 3 compared to Grade 2 patients) [43]. Thus, it can be presumed that increased SIRT1 serum levels were associated with some particular and rather aggressive tumors (colorectal and breast cancers) and tumor differentiation grades. The LSCC, on the contrary, is a relatively less aggressive tumor considering rather low local spreading and low metastatic rate [62, 63]. Therefore, LSCC possibly does not cause SIRT1 serum level increment. Consequently, the role of SIRT1 serum levels as an indicator of the prognosis of LSCC remains doubtful.

On the other hand, Noguchi et al. assessed the SIRT1 expression immunohistochemically using surgical samples from 437 consecutive head and neck squamous cell carcinoma (HNSCC) patients. Results of the study showed that the SIRT1 expression acted as a tumor suppressor and served as an indicator for a good prognosis [33]. Yu et al. investigated SIRT1 expression in laryngeal and hypopharyngeal squamous cell carcinoma (HSCC) tissue samples using immunohistochemical staining and its correlations with clinical parameters. They found a significant correlation between the decreased SIRT1 expression and clinical tumor stage, metastasis to the neck lymph nodes, and the patient’s survival rate. The authors concluded that SIRT1 acts as a tumor suppressor in LSCCs and HSCC [64]. However, those authors pulled their LSCC and HNSCC patients into one group; therefore, these results cannot be directly compared to the cohort of pure LSCC patients used in the present study. On the other hand, the results of the current study may suggest that in cases of LSCC, the SIRT1 serum levels remain unchanged despite the increment of SIRT1 expression directly in the tumor tissue. This phenomenon may be caused by a relatively low tumor suppressor activity of SIRT1 related to the less aggressive nature of LSCC.

The strength of the present study is a relatively large and homogenous group of pure LSCC patients (302 subjects) and age and sex-matched controls (409 subjects). This specific feature ensured a comprehensive analysis of associations between SIRT1 serums levels and selected SIRT1 SNPs and the development of a particular tumor in one anatomical region of the head and neck, i.e., LSCC.

Several limitations of the present study must be considered. The sample size for analysis of serum concentration levels of SIRT1 was limited and too small to reach the desired power setting. Therefore, the results obtained in the present study regarding the associations between the SIRT1 serum concentration levels and LSCC should be considered as the tendency. Further investigation with a large enough sample size is foreseen to confirm the possible role of serum concentration levels of SIRT1 in LSCC development. The data about smoking and alcohol consumption was available and analyzed in a limited cohort of study participants that did not match the patient and control groups. Therefore, the impact of smoking and alcohol consumption habits was not completely investigated. However, this is the target task for future investigation.

5.Conclusion

The present study showed a statistically significant association between SIRT1 rs3758391T/T genotype and increased odds of LSCC development, as well as increased LSCC development into the advanced stages and T4 odds. Also, SIRT1 rs3818292 and rs7895833 SNPs revealed increased odds of LSCC development into T3 and T4. LSCC patients with SIRT1 rs3818292 AG genotype showed a tendency to manifest with lower SIRT1 serum levels. No associations between SIRT1 (rs3818292, rs3758391, and rs7895833) SNPs and the 5-year survival rate of LSCC patients were found in the present study. Therefore, the role of SIRT1 in cancer, including LSCC, remains incompletely understood. Further research is needed to investigate possible mechanisms of the associations found, before selecting candidates for prognostic factors or a future therapeutic target.